Merck has filed an IND with the FDA for a cancer vaccine candidate that targets telomerase. Merck is developing the vaccine under a July, 2005 Research, Development and Commercialization License Agreement with Geron Corp., which provided exclusive worldwide rights to develop and commercialize non-dendritic cell-based vaccines targeting telomerase. Geron received a $4 million milestone payment from Merck after the IND filing, and is eligible to receive additional development milestones as well as...